Shares of Prima BioMed Ltd (NASDAQ:IMMP - Get Free Report) passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.70 and traded as low as $1.61. Prima BioMed shares last traded at $1.61, with a volume of 127,779 shares trading hands.
Analyst Ratings Changes
Separately, Wall Street Zen downgraded shares of Prima BioMed from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $7.00.
Check Out Our Latest Stock Analysis on Prima BioMed
Prima BioMed Price Performance
The stock's 50 day moving average is $1.70 and its 200-day moving average is $1.73.
Hedge Funds Weigh In On Prima BioMed
A hedge fund recently raised its stake in Prima BioMed stock. Jane Street Group LLC increased its position in shares of Prima BioMed Ltd (NASDAQ:IMMP - Free Report) by 14.7% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 51,574 shares of the biotechnology company's stock after purchasing an additional 6,617 shares during the quarter. Jane Street Group LLC's holdings in Prima BioMed were worth $91,000 as of its most recent SEC filing. Institutional investors own 2.32% of the company's stock.
About Prima BioMed
(
Get Free Report)
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.
Recommended Stories
Before you consider Prima BioMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prima BioMed wasn't on the list.
While Prima BioMed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
